QCMA
LPCN icon

Quad Capital Management Advisors’s Lipocine LPCN Stock Holding History

Quad Capital Management Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,588
Closed -$124K – 42
2019
Q3 		$124K Buy
2,588
+1,176
+83% +$47.2K 0.06% 70
2019
Q2 		$47K Buy
+1,412
New +$43.6K 0.02% 65
2018
Q2 		– Sell
-1,235
Closed -$32 – 115
2018
Q1 		$32 Buy
+1,235
New +$34.4K ﹤0.01% 77

Other funds holding LPCN

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
CL
Choreo LLC Rockford, Illinois $8.15B AUM 20.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Quad Capital Management Advisors's LPCN Position: Q4 2019 in Review

Quad Capital Management Advisors sold out of Lipocine (LPCN) in Q4 2019, closing a stake of 2,588 shares — an estimated $124K sold.

Quad Capital Management Advisors first reported a position in LPCN in Q1 2018 and held it in 3 quarters. The position peaked at $124K in Q3 2019. 32 funds tracked by Wall St. Rank hold LPCN as of Q4 2019.

  • Quad Capital Management Advisors reported no remaining Lipocine position as of Q4 2019 after selling out during the quarter.
  • Quad Capital Management Advisors sold 2,588 Lipocine shares in Q4 2019, an estimated $124K.
  • Quad Capital Management Advisors first reported a position in Lipocine in Q1 2018 and held it in 3 quarters.
  • Quad Capital Management Advisors's Lipocine position peaked at $124K in Q3 2019.
  • 32 funds tracked by Wall St. Rank held Lipocine as of Q4 2019.

Based on Quad Capital Management Advisors's 13F filing for Q4 2019, filed 9 Jan 2020.